India’s First FDA-Approved Antimicrobial Drug Offers Hope in the Fight Against Resistance

India, one of the countries most severely affected by antimicrobial resistance (AMR), has made a significant breakthrough in the battle against antibiotic-resistant infections. In 2019, these infections were responsible for approximately 300,000 deaths in India alone, with nearly 60,000 newborns losing their lives annually due to antibiotic resistance.

A promising new drug, Enmetazobactam, developed by Chennai-based Orchid Pharma, has become the first antimicrobial invented in India to receive approval from the US Food and Drug Administration (FDA). The injectable medication targets bacterial defense mechanisms, rather than attacking the bacteria directly, making it an innovative solution for treating severe infections.

Enmetazobactam has proven effective in treating critical conditions such as urinary tract infections (UTIs), pneumonia, and bloodstream infections. After undergoing trials across 19 countries involving over 1,000 patients, the drug has received approval from global regulatory bodies for its efficacy.

Dr. Maneesh Paul, the lead co-inventor of the drug, explained to the BBC that the drug “has shown remarkable potency against bacteria that have evolved over the years.” Administered via intravenous infusion in hospitals, it is designed for critically ill patients and is not available over the counter.

This breakthrough marks a significant step in addressing the growing challenge of antimicrobial resistance, offering hope for patients with infections that are increasingly difficult to treat due to resistant bacteria.